Blockbusters (such as Humira, Enbrel and Herceptin) achieved huge success because of proven clinical efficacy, strong market demand, thourough IP protection and market penetration strategies. The strict R&D standards are the cornerstones of blockbuster.
In the past 10 years, GenScript has been sticking to the "blockbuster" standards to manage, research and deliver every therapeutic programs. GenScript delivers humanized, human and bispecific antibody leads with good biological efficacy, safety & manufacturability in 12-15 months, as your one-stop solution from Targets to Therapeutic Antibody Candidates.
|Functional Ab Lead||Antibody Lead
|Functional Optimized Lead with good manufacturability||Antibody Lead
|Optimized Lead with good biological efficacy, safety & manufacturability||In Vivo Efficacy, Exploratory PK & Toxicity Studies|
|Discovery Services||Testing Options||Deliverables||Timeline|
|M1: Antibody Lead Generation||Bioassays||
||Biochemical & Biophysical Assays
|M2: Antibody Lead Optimization||In Vivo Efficacy, Exploratory PK & Toxicity Studies||
|Ligand||Analyte||ka (1/Ms)||kd (1/s)||KD (M)||Rmax (RU)||Chi² (RU²)|
|Humanized Ab Lead||7.05E±05||1.00E-05||1.42E-11||38.2||5.28E-02|
|Thermostability (Tm)||>60 °C (by DSC)|
|Extra Cys||No hotspot predicted, confirmed by Mass Spec|
|Oxidation||2 hot spots predicted and confirmed by Mass Spec,
Not impact binding by Biacore & on stability by SEC under forced oxidation
Our customer service representatives are available 24 hours a day, Monday through Friday to assist you.